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ABSTRACT
Objectives: The aim of the present study was to
estimate the cost-effectiveness of the polypill in the
primary prevention of cardiovascular disease.
Design: A health economic modelling study.
Setting: Primary healthcare in the Netherlands.
Participants: Simulated individuals from the general
Dutch population, aged 45e75 years.
Interventions: Opportunistic screening followed by
prescription of the polypill to eligible individuals.
Eligibility was deﬁned as having a minimum 10-year
risk of cardiovascular death as assessed with the
Systematic Coronary Risk Evaluation function of
alternatively 5%, 7.5% or 10%. Different versions of
the polypill were considered, depending on
composition: (1) the Indian polycap, with three
different types of blood pressure-lowering drugs,
a statin and aspirin; (2) as (1) but without aspirin and
(3) as (2) but with a double statin dose. In addition,
a scenario of (targeted) separate antihypertensive and/
or statin medication was simulated.
Primary outcome measures: Cases of acute
myocardial infarction or stroke prevented, quality-
adjusted life years (QALYs) gained and the costs per
QALY gained. All interventions were compared with
usual care.
Results: All scenarios were cost-effective with an
incremental cost-effectiveness ratio between V7900 and
12300 per QALY compared with usual care. Most health
gains were achieved with the polypill without aspirin and
containing a double dose of statins. With a 10-year risk
of 7.5% as the threshold, this pill would prevent
approximately 3.5% of all cardiovascular events.
Conclusions: Opportunistic screening based on global
cardiovascular risk assessment followed by polypill
prescription to those with increased risk offers a cost-
effective strategy. Most health gain is achieved by the
polypill without aspirin and a double statin dose.
INTRODUCTION
In a by now famous article in the British
Medical Journal in 2003, Wald and Law
1
suggested that a ‘polypill’ could be of great
beneﬁt in the prevention of cardiovascular
disease (CVD). As originally proposed, such
a pill would consist of a combination of drugs
with proven efﬁcacy and safety in reducing
cardiovascular risk, in particular three
different types of blood pressure-lowering
drugs (a b blocker, an antidiuretic and an
ACE inhibitor), one lipid-lowering drug, an
antiplatelet agent (aspirin) and folic acid to
reduce serum homocysteine. In combina-
tion, lower dosages could be used resulting in
ARTICLE SUMMARY
Article focus
- Cardiovascular diseases continue to be still a major,
partly preventable, cause of illness and death.
- A polypill that lowers by targeting several risk
factors simultaneously is in line with the concept
that the aim in primary prevention should be to
bring down ‘global’ cardiovascular risk.
- The aim of this study was to estimate the
potential cost-effectiveness of polypill prescrip-
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Open Access Researchgreater efﬁcacy than single medication with a more
favourable safety proﬁle than higher dosages of indi-
vidual drugs.
CVDs are still a major cause of illness and death. For
example, estimates show that in the year 2006 >80
million people in the USA had one or more forms of
CVD.
2 In 2009, CVD was responsible for 29% of all
deaths in the Netherlands, taking second place after
cancer (32%) as the most important cause of death.
3
Ischaemic heart disease and stroke together were
responsible for 27% of all hospitalisations.
4
As CVD is the result of a gradual process of athero-
sclerosis building up over many years, the most rational
strategy is stopping, or at least slowing down, the progress
of plaque formation. For those whose risk factor levels put
them at increased risk, life style measures or medication
are available for primary prevention but identifying who
might beneﬁt and what measures are most appropriate is
subject of much discussion.
5e8 The recognition that
atherosclerotic CVD is the product of multiple interacting
risk factors has in the past decades led to new approaches
in prevention. In particular, the concepts of global risk,
being the aggregate risk of all risk factors together and
total CVD risk assessment have emerged as an important
inspiration for developing guidelines on cardiovascular
risk management.
9 Examples of methods of global risk
assessment are the well-known Framingham risk score
and the Systematic Coronary Risk Evaluation (SCORE),
the latter based on a pooled data set of 12 European
cohort studies.
10 A consequence of the global risk
approach is that the focus of intervention shifts from
treatment of individual risk factors to placing emphasis
on reducing total CVD risk, irrespective by what means.
Thus, the idea of a polypill, that lowers risk by targeting
more than one risk factor simultaneously, seems perfectly
tailored to this strategy.
11 In addition, it provides a ‘one
stop shop’ when someone could beneﬁt from more than
one type of medication.
Up to the present, no evidence for the effectiveness of
such a polypill exists. Yet, randomised clinical trials with
several versions of a polypill have been started. The
Indian Polycap Study was a phase II, randomised double-
blind clinical trial designed to test the effects of a version
of the polypill on intermediate measures for the devel-
opment of CVD, in particular blood pressure, cholesterol,
heart rate and urinary dehydrotromboxane B2.
12 The
polypill used in this randomised controlled trail differed
from the one suggested by Wald and Law by omitting folic
acid, as the supposed effects of folic acid on serum
homocysteine have not been conﬁrmed.
13 Medication
was only given for a period of 12 weeks in the Polycap
Study.
Even though there is still no evidence regarding the
efﬁcacy of a polypill on hard endpoints (acute myocar-
dial infarction, stroke), the extensively validated relation
between blood pressure and cholesterol level on the
one hand and disease risk on the other allows a ﬁrst
exploration of the range of costs and beneﬁts that
might be expected from the polypill in the prevention of
CVDs.
The aim of this study was to estimate the potential cost-
effectiveness of the polypill in the primary prevention of
myocardial infarction and ischaemic stroke. In order to
explore this issue, a scenario of opportunistic screening
in primary care was taken as point of departure. Patients
were eligible for prescription of the polypill starting
from a 5% risk up to 10% risk of cardiovascular death in
10 years, based on their SCORE function.
14
METHODS
We conducted a simulation study using a computer
model (RIVM Chronic Disease Model (CDM)) devel-
oped at our institute.
15 16 Point of departure for the
simulations was a scenario, in which the polypill is
offered to eligible patients identiﬁed during routine
visits to their general practitioner (GP) (‘opportunistic
screening’). The GP takes the initiative suggesting to
patients to determine their 10-year risk for cardiovas-
cular mortality. Those aged 40e75 years without known
previous CVD are eligible for the screening. Starting
from risk levels of $5%, people will be offered lifelong
preventive medication. Cardiovascular mortality risk is
assessed using the SCORE risk function developed and
recommended by the European Society of Cardiology
and endorsed in the Netherlands by professional and
patients’ organisations.
17 The score function is calcu-
lated using age, sex, blood pressure, cholesterol and
smoking status as input.
The current Dutch guideline for primary cardiovas-
cular prevention, which was introduced in 2006,
recommends the SCORE risk charts to determine treat-
ment recommendations. For this purpose, a version of
the SCORE was developed adapted to Dutch risk factor
and mortality data.
14 It is the algorithm for this version
that we used in our analyses.
According to the Dutch guideline, for individuals with
a 10-year risk of cardiovascular death of $10% targeted
drug therapy is recommended: antihypertensive treat-
ment when systolic blood pressure (SBP) $140 and
statins when low-density lipoprotein (LDL) cholesterol
>2.5 mmol/l. When risk exceeds 5%, life style counsel-
ling should be considered. Aspirin is recommended for
ARTICLE SUMMARY
Strengths and limitations of this study
- Strong point of the study is that different compositions of the
polypill have been modelled. Also, realistic estimates for
adherence and compliance have been used.
- As only preliminary results of a phase II clinical trial on efﬁcacy
of the polypill were available, we had to apply mathematical
modelling to estimate cost-effectiveness. This provides insight
into the range of health beneﬁts that can be expected. Pending
results with regard to established clinical endpoints from large-
scale phase III trials, the results of this study should not be
taken as a precise estimate of the cost-effectiveness of the
polypill.
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Cost-effectiveness of the polypillsecondary prevention only.
18 Following the rationale
that arguments for the polypill are based on the expec-
tancy of a more favourable beneﬁt versus safety proﬁle,
we assumed that, in a situation where a polypill would be
available, it would be considered to lower the threshold
for prescribing preventive medication. On the other
hand, it seems unlikely that preventive medication would
be considered for everyone, even those with risks below
5%. Therefore, in order to assess the effect of different
choices for the threshold, we performed analyses for
different cut-points: 5%, 7.5% and 10%, the threshold
for drug treatment of the present guideline.
The RIVM chronic disease model
The CDM is a computer simulation model designed to
be able to simulate the evolution of several chronic
diseases in relation to risk factor levels in the Dutch
population. It includes the most common chronic
diseases, among which chronic obstructive pulmonary
disease, diabetes mellitus type 2, myocardial infarction
and stroke, and in addition a number of life style-related
risk factors, such as smoking, blood pressure and
cholesterol. It may be best characterised as a Markov-
type multistate-transition model.
15 16 The model
describes the development over time of demography,
risk factor prevalence, disease incidence and mortality,
in 1-year time steps. As input, it takes the age and sex
composition of the current Dutch population as well as
its distribution according to risk factor levels. It further
requires speciﬁcation of three types of transition prob-
abilities (the probability of going from one state to
another in 1-year time): between risk factor levels,
between disease states (ie, disease incidence), for each
disease in the model. Disease incidence and mortality
depend on risk factor levels and the presence of other
diseases via relative risks (RRs). Estimates of RRs were
derived from literature, whereas incidence, prevalence,
transition rates and mortality rates in the model apply to
the Dutch population. In addition, each disease is
associated with average yearly, per patient, costs and
with disability weights. All data are age and sex speciﬁc.
The model further allows specifying alternative
‘scenarios’, by adjusting the input parameters and
comparing the results obtained with other scenarios
with the ‘reference scenario (see below)’. Healthcare
costs were based on costs-of-illness studies in the
Netherlands,
19 20 and the healthcare outcome measure
‘quality-adjusted life year (QALY)’ was computed using
the Global and Dutch burden of disease studies.
21e24
Scenarios
Several scenarios were deﬁned based on (1) different cut-
off levels for 10-year risk: 5%, 7.5% and 10% and (2)
different compositions of the polypill. These scenarios
were compared with the reference scenario of care as
usual and with each other. Usual care is represented in
our model in the reference scenario by the proportion of
individuals currently being treated with statins and/or
antihypertensive agents, based on data from the Doetin-
chem Cohort Study (details about this study follow
later).
25 It is assumed that individuals already being
treated with drugs will not switch to the polypill. We
further assume that people identiﬁed as being at risk by
opportunistic screening would otherwise not receive
preventive medication. In other words, the polypill was
prescribed only to unexposed individuals who did not
already use one of the drugs included in the polypill. The
different scenarios explored using the CDM model are:
(1) The reference scenario represents the expected
evolution of the health status and risk factor distribution
of the Dutch population as simulated by the model using
the basic input parameters that represent the relevant
characteristics of the current Dutch population (current
practice).
(2) The polypill scenarios simulate the situation in which
all eligible individuals, not yet treated with statins or
antihypertensive agents, and selected by ‘opportunistic
screening’, are offered lifelong medication. Besides the
original Indian ‘Polycap’ composition, we also consid-
ered different versions of the polypill without aspirin
that would avoid the bleeding risks associated with
antiplatelet agents. Thus, the following alternative
compositions of polypills were considered:
(2A) The ‘Indian polycap’, consisting of 20 mg simvas-
tatin, 12.5 mg thiazide, 5 mg ramipril, 50 mg atenolol
and 100 mg aspirin.
(2B) As (2A) but without aspirin.
(2C) As (2B) but with 40 mg simvastatin (double dose
statins, ie, Dutch standard dose when given as mono-
therapy).
Finally, an alternative scenario was deﬁned (scenario 3:
‘separate medication’) in which screened individuals
eligible for the polypill will not be offered the polypill,
but rather medication tailored to the underlying risk
factor: a statin in case of hypercholesterolaemia, an
antihypertensive in case of hypertension, both or none
(ie, the risk score is increased, but blood pressure and
hypertension are below the respective cut-points).
Basically, the analyses compare the scenarios in which
medication is offered in primary care to all eligible
individuals in the age group 40e75 years with the
scenario in which usual care is continued. The compar-
ison thus is between a hypothetical population with one
of the interventions described above and one without,
where in all other respects the populations are equal at
baseline and represent the current Dutch population.
The model is ‘run’ until all have died and no ‘inﬂow’ of
younger individuals is taken into account.
Below, we describe how we derived values for the
relevant parameters for each scenario.
Estimation of the number of eligible individuals and of the
proportion who would be treated
In order to estimate the numbers of individuals who
would receive the polypill, the following steps were taken
(ﬁgure 1).
First, the proportion of the population aged
40e75 years without a history of CVD and not yet treated
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Cost-effectiveness of the polypillwith statins or antihypertensives was estimated. To this
end, we applied the SCORE algorithm to the most
recent data of the Doetinchem Cohort Study. The
Doetinchem Cohort Study is a prospective study of
>5000 inhabitants of the city of Doetinchem and
surroundings who were included in the years
1987e1991. Participants were aged 20e65 years at
inclusion and have been followed for >20 years now. So
far, four rounds of data collection have been completed,
roughly at 5-year intervals. We used the data of round 4,
collected during the years 2003e2007. Among the data
collected, all variables necessary to calculate the SCORE
are included (age, sex, SBP, LDL cholesterol, smoking
status, treatment status of statins and antihypertensive).
The Doetinchem cohort has been described elsewhere.
25
The cohort represents the best available source for the
Netherlands to determine the current population
distribution of risk factors.
Next, we needed to estimate how many people would
be reached by opportunistic screening.
Data taken from Statistics Netherlands show that
approximately 75% of the Dutch population visit their
GP at least once every year.
26 We assumed that this ﬁgure
also applies to our target population. We further
assumed that the GP offers a screening consultation to
all in the target population (those aged 40e75 years) in
the year of the intervention and that 50% of the invited
population consent. Risk assessment consists of one
consultation with the GP, who explains the procedure,
measures blood pressure and draws blood for a labora-
tory test of blood cholesterol. The patient is then invited
for a second consultation to calculate the SCORE and
discuss the consequences.
We ﬁnally assumed that of those who are offered the
polypill (SCORE $5%, 7.5% or 10%) or a separate
statin/antihypertensive, 85% will decide to take the pill
for at least 1 year
12 and that compliance rates would
stabilise at 50% after 5 years. A ﬂow chart of the process
of screening and selecting patients is shown below: for
the separate medication scenario (scenario 3), we
assumed that adherence (willingness to start with the
therapy) to the antihypertensive was 90% and adherence
to the statin was 60%,
27 which fraction was multiplied by
the before-mentioned compliance rate to achieve overall
compliance (willingness to continue the therapy).
Effects
A crucial parameter in implementing the polypill
scenarios is the measure of its efﬁcacy, in particular the
RR reduction: the RR for acute myocardial infarction or
stroke after taking the medication compared with the RR
before taking it (or in a control (placebo) group).
Unfortunately, as mentioned above, so far there are no
data on the effects of the polypill on cardiovascular
events. Instead, we will have to base our estimate on the
effects on ‘intermediate’ measures, that is, blood pres-
sure and cholesterol. In particular, we use the outcomes
of the Indian Polycap Study.
12 As mentioned above, the
Indian polypill consist of three blood pressure-lowering
drugs: hydrochlorthiazide 12.5 mg (a diuretic), atenolol
Figure 1 Flow chart of
participation.
Dutch population 40–75 years old without known cardiovascular 
disease
N=7 000 000
75% visist GP
N=5 250 000
50% undergoes screening
N=2 625 000
31.3% has a score ≥7.5%
N=822 000
85% initial adherence
N=699 000
40.3% has a score ≥5%
N=1 058 000
85% initial adherence
N=899 000
24.7% has a score ≥10%
N=648 000
85% initial adherence
N=551 000
50% compliance after 5 
years N=529 000
50% compliance after 
5 years N=411 000
50% compliance after 5 
years N=324 000
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Cost-effectiveness of the polypill50 mg (a b blocker) and ramipril 5 mg (an ACE inhib-
itor); a lipid-lowering drug (simvastatin 20 mg) and an
antiplatelet (aspirin 100 mg). The effect of the polypill
on blood pressure was a lowering of the diastolic blood
pressure with 5.7 mm Hg (95% CI 4.7 to 6.4) and of the
SBP with 7.4 mm Hg (95% CI 6.1 to 8.1). The LDL
cholesterol was reduced by 0.80 mmol/l (95% CI 0.62 to
0.78).
12
These effects on blood pressure and cholesterol are
substantially lower than what Law and Wald predicted.
Thus, the RR reductions suggested in their article and in
the accompanying meta-analysis of combination treat-
ment with blood pressure-lowering drugs
28 could not be
relied upon for our purposes. Instead, we took as a basis
the reductions in blood pressure and cholesterol
observed in the Polycap Study and translated these into
corresponding RR reductions using meta-analyses
providing estimates of these relations.
Blood pressure lowering
For blood pressure, we used a recent meta-analysis of
the Blood Pressure Lowering Treatment Trialists’
Collaboration.
29 Although the published article only
reported results for ‘major cardiovascular events’ as
outcome, supplementary analyses for stroke and coro-
nary heart disease separately were obtained from the
a u t h o r s .F o re a c h5 m mH gr e d u c t i o ni nS B P ,t h e
following RRs were found for stroke, 0.83 (95% CI 0.74
to 0.94) for those under 65 years of age and of 0.91
(95% CI 0.84 to 0.99) for those aged 65 years or older;
for coronary heart disease, 0.87 (95% CI 0.80 to 0.95)
and 0.90 (95% CI 0.84 to 0.98), respectively, and for
total mortality, 0.92 (95% CI 0.85 to 0.99) and 0.96
(95% CI 0.91 to 1.02), respectively. The relation
between blood pressure reduction achieved and risk
reduction was found to be log linear. Moreover, the
authors compared various drug classes and concluded
that there were no differences on the effects of lowering
blood pressure according to drug class. Also when
combinations of drugs are given, the effect on risk has
been found to depend only on the reduction in blood
pressure achieved.
28
Assuming the ﬁndings of this meta-analysis, we calcu-
lated the RRs corresponding to a 7.4 mm Hg reduction
by raising the RRs to the power (7.4/5). This resulted in
the following RRs: for stroke, 0.76 (95% CI 0.91 to 0.64)
for those under 65 years of age and 0.87 (95% CI 0.98 to
0.77) for those aged 65 years or older; for coronary heart
disease, 0.82 (95% CI 0.92 to 0.72) and 0.86 (95% CI
0.96 to 0.77) respectively, and for total mortality, 0.88
(95% CI 0.99 to 0.79) and 0.94 (95% CI 1.03 to 0.87),
respectively.
For separate treatment, we took treatment with
a diuretic or b blocker as standard. From a meta-analysis
by the Blood Pressure Lowering Treatment Tria-
lists’Collaboration,
30 which compared various blood-
lowering agents both with each other and to placebo, we
inferred that on average a diuretic results in a reduction
of 7.2 mm Hg. As this is almost the same as the reduc-
tion achieved by the polypill, we used the same RR
reduction values.
Cholesterol lowering
For statins, we used a recent meta-analysis by the
Cochrane Collaboration on statins for the primary
prevention of CVD.
31 The mean difference in LDL
cholesterol between treatment groups and controls was
 0.92 (95% CI  1.10 to  0.0.74), corresponding to RRs
of 0.72 (95% CI 0.65 to 0.79) for coronary events, 0.78
(95% CI 0.65 to 0.94) for stroke and 0.84 (95% CI 0.73
to 0.96) for total mortality. As the reduction found in the
Polycap Study was 0.80, we adjusted the RRs reported for
the meta-analysis by raising them to the power 0.80/0.92.
This is based on the assumption that the RR has a log-
linear relation with the reduction in cholesterol level
(each millimoles per litre reduction reduces the risk by
the same factor), for which there is much evidence.
32
After this adjustment, we found the following RRs: for
coronary heart disease events, it was 0.75 (95% CI 0.69 to
0.82); for stroke, it was 0.81 (95% CI 0.69 to 0.95) and
for total mortality, it was 0.86 (95% CI 0.76 to 0.97).
Again, assuming the log linearity between level reduc-
tion and RRs, we calculated for the double dose the
following RRs: for coronary heart disease events, it was
0.52 (95% CI 0.42 to 0.62); for stroke, it was 0.61 (95%
CI 0.42 to 0.88) and for total mortality, it was 0.71 (95%
CI 0.53 to 0.92).
In the literature, no difference was found in the
number of adverse events or in the number of individ-
uals who developed cancer or myalgia.
31 33 34
Antiplatelet effects
A recent meta-analysis of aspirin in the primary preven-
tion of vascular disease
35 found the following RRs for the
treatment group versus the control group: any major
coronary event 0.82 (95% CI 0.75 to 0.90) and no
signiﬁcant net effect on stroke (decrease in ischaemic
strokes annulled by an increase in haemorrhagic
strokes).
Table 1 gives an overview of the risk reductions used
due to simvastatin, the blood pressure-lowering agents
and aspirin. RRs of those using medication versus those
without medication as used in the model are expressed
separately for the different types of medication. Effects
are assumed to be independent. To calculate the
aggregate effect of a particular combination RRs are
multiplied.
Costs
Costs were determined from the perspective of the
healthcare payer and according to the national guide-
line for costing research in health economic analysis.
36
Direct medical costs associated with diseases per patient
per year were included in the CDM.
19 20 Costs due to all
medical treatment in life years gained (indirect medical
cost) are automatically included in the model.
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Cost-effectiveness of the polypillCosts for screening and drug use
Unit costs, including costs for GP visits, laboratory
testing, medication and drug delivery, are presented in
table 2.
Costs during the ﬁrst year consist of two GP visits, one
laboratory test and if indicated the costs of medication
and drug delivery.
During the second and subsequent years, the costs
consist of one GP visit (control visit), one laboratory test
and the costs of drug delivery.
As currently the polypill is not yet on the market,
a price had to be estimated based on its ‘ingredients’. We
took as our reference the costs per milligrams of statins,
b blockers, ACE inhibitors and aspirin prescribed as
generics in the Netherlands, and we assumed that the
price of a pill would be the sum of the prices of its
components.
37 Thus, the Polycap pill (scenario 1) would
cost V89.75 per year, including fees for prescription and
drug delivery.
Costs and effects associated with adverse events
The frequency of adverse effects of the use of statins and
antihypertensive agents has consistently been reported
to be very low. We assumed that the costs and effects due
to these agents are captured by taking into account non-
adherence and stopping taking the pill. The adverse
effects of aspirin, however, are known to be more severe.
In particular, the risks of major bleedings should be
taking into account. The increased risk of hemorrhagic
stroke is already incorporated in our estimate of the RR
for stroke (see above). The costs and (negative) effects
of gastrointestinal bleedings caused by the use of aspirin
were added to the model in the following manner. The
incidence rate of gastrointestinal bleedings was esti-
mated to 8.5/year/1000 patients.
38 The loss of utility
caused by gastrointestinal bleedings was estimated to be
0.06.
39 The costs of gastrointestinal bleeding were esti-
mated at V3425, according to the Dutch Diagnosis-
Related Group tariff (http://www.nza.nl).
Table 1 RRs versus no medication (95% CI)
RR Statin 20 mg Statin 40 mg BPL in PP BPL separate Aspirin
Total mortality 0.86 (0.76 to 0.97) 0.71 (0.53 to 0.92) 0.91 (0.83 to 1.00) 0.91 (0.83 to 1.00) 1
CVA 0.81 (0.69 to 0.95) 0.61 (0.42 to 0.88) 0.81 (0.70 to 0.94) 0.81 (0.70 to 0.94) 1
AMI 0.75 (0.69 to 0.82) 0.52 (0.42 to 0.62) 0.84 (0.74 to 0.94) 0.84 (0.74 to 0.94) 0.82 (0.75 to 0.90)
AMI, acute myocardial infarction; BPL, blood pressure-lowering drug; CVA, cerebrovascular accident; PP, polypill.
Table 2 Intervention costs
Item Unit
Costs per
unit/quantity in PP
Costs per
person per year
GP visit* Standard
consultation
V29 V58 (ﬁrst year)
V29 (subsequent years)
Blood drawing Included
Laboratory V1.70 V1.70
Drug costsy
Simvastatin 20 mg dd 1 year V6.69 V6.69
Simvastatin 40 mg 1 year V13.39 V13.39
Ramipril 2.5 mg 1 year V22.48 V22.48
Atenolol 50 mg 1 year V22.48 V22.48
Thiazide 12.5 mg 1 year V3.47 V3.47
Aspirin 100 mg 1 year V3.70 V3.70
Drug delivery costsz First delivery V5.74
Per 3 months V5.74 V28.70 (ﬁrst year)
V22.96 (subsequent years)
Repeat prescriptionz Included in basic tariffs
Gastrointestinal bleeding (adverse event)z V3425 V3425
Costs in the ﬁrst year consist of two GP visits, one laboratory test, four times drug delivery and an additional charge for ﬁrst drug delivery. Costs
in subsequent years: one GP visit plus one laboratory test plus four times drug delivery costs.
*Fees in the Netherlands are determined by the national regulator of healthcare tariffs: Nederlandse Zorgautoriteit (National Health Authority). In
addition to costs per visit, GPs are paid for each patient registered in their practice on a yearly basis (http://www.nza.nl). Consulted on 16 June
2011.
yDrug costs are based on the costs as calculated and publicised by the College for Health Insurance, which determines the prices for
reimbursement (pharmacotherapeutic compass: http//www.cvz.nl/kompas).
zAccording to maximum fees set for the year 2011 by National Health Authority (nza, ‘tariefbeschikking’ nr. TB/CU-5000-01, nr. 34, http://www.
nza.nl).
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Cost-effectiveness of the polypillTotal costs
Total costs were calculated by multiplying unit costs with
volumes. Volumes were derived by determining the
‘numbers of units per patient’ and the numbers of
patients at each stage in the process: ﬁrst screening, then
start therapy, ﬁrst year and ﬁnally all subsequent years of
the simulation.
Cost-effectiveness
The main endpoint of this study was the cost-effectiveness
ratio expressed as the ratio of the difference in costs and
the difference in QALYs when comparing the alternative
scenarios with the reference scenario (Cost/QALY).
As the rationale for prescribing the polypill is to
prevent CVD, we also determined the numbers of
myocardial infarctions and strokes prevented in the
different scenarios. This was done by calculating the
differences in the cumulative incidences between
scenarios. Finally, these ﬁgures were used to estimate the
numbers of patients that would have to be treated
(number needed to treat) to prevent one myocardial
infarction or one stroke. Taking into account time
preferences, future costs and effects were discounted
according to the Dutch guideline, with a discount rate of
4% for costs and 1.5% for effects.
36 The chosen time
horizon was a lifetime horizon.
Probabilistic sensitivity analyses
As several important assumptions had to be made in
modelling the cost-effectiveness of the polypill, we
explored the range of likely outcomes with a probabilistic
multivariate sensitivity analysis. The key variables with
known uncertainty were screening acceptance, adherence
to medication, RRs for developing stroke and myocardial
infarction, and the RR for all-cause mortality. Screening
acceptance was taken to be distributed as a b distribution
(a¼5, b¼5) so that the average acceptance was 0.50, with
a 95% CI of (0.21 to 0.79). First year’s adherence was
taken from a b distribution (a¼42.5, b¼7.5) so that the
average ﬁrst year’s adherence was 0.85, with a 95% CI of
(0.74 to 0.93). The RRs were randomly taken from
b distributions with characteristics as mentioned in table
1. We performed 350 simulations in total.
Another key parameter in the model was the price of
the polypill. Because the polypill is not commercially
available (yet), its price is unknown. As the best estimate,
we used the sum of the costs of the separate elements of
the polypill. However, if pill prices will be largely deter-
mined by production costs, it is likely that the pill will be
considerably cheaper than the sum of the costs of its
components. On the other hand, if, for instance the
added value to the consumer of having to take one pill
only will be priced in, it cannot be ruled out that the
price will be higher. For lack of an informed estimate of
price ranges, we explored an array of possible values in
order to compare with the costs of separate medication.
We performed also analyses with different discount rates.
RESULTS
Descriptives
Table 3 shows the proportion of individuals eligible for
medication based on a 10-year risk of cardiovascular
mortality threshold of 5%, 7.5% or 10%. For example,
with a threshold of 7.5%, of all persons between 40 and
75 years, >31% was eligible for medication. The ﬁrst half
of the table concerns those eligible for the polypill and
the second half those eligible for separate medication,
based on having a SCORE risk of $7.5% together with
hypertension and/or hypercholesterolaemia (‘separate
medication scenario’, scenario 3).
Effectiveness
Table 4 shows that by using the polypill as described for
scenario 2C, the number of cases of acute myocardial
infarction or stroke prevented, almost 30, respectively 47
thousand for a threshold of 7.5% (5% and 10% not
shown), was more than for the other polypill scenarios. It
should be noted that the total health gain in the separate
medication scenario (scenario 3) is more than 1/2 of the
total health gain of scenario 2C.
Cost-effectiveness
Table 5 shows the incremental cost-effectiveness ratios
(ICERs) for all scenarios. The ratios do not differ very
much between the three SCORE cut-off values consid-
ered and are all well within accepted ICER thresholds.
Table 3 Individuals* eligible for the polypill and separate medication (% of total population)
Risk threshold
Polypill Separate medication
Men Women Total Men Women Total
5% 7.5% 10% 5% 7.5% 10% 5% 7.5% 10% 5% 7.5% 10% 5% 7.5% 10% 5% 7.5% 10%
Age, years
40e49 9.1 2.2 0.4 0.0 0.0 0.0 4.0 1.0 0.2 8.7 2.1 0.4 0.0 0.0 0.0 3.8 0.9 0.2
50e59 61.3 38.3 22.7 6.0 1.7 0.5 32.1 19.0 11.0 50.7 32.8 20.1 5.8 1.7 0.5 27.2 16.5 9.8
60e69 98.8 93.4 83.5 72.1 47.5 30.0 85.7 70.9 57.2 74.9 73.3 68.1 61.3 41.2 26.5 68.2 57.6 47.7
70e75 98.9 98.9 98.4 100.0 97.0 87.0 99.4 98.0 92.9 72.7 72.7 72.7 76.3 75.8 71.1 74.5 74.2 71.9
All ages
(40e75)
57.4 46.2 37.7 25.0 18.0 13.1 40.3 31.3 24.7 46.2 37.8 31.5 21.9 16.0 11.9 33.4 26.3 21.2
*Not yet using statins or antihypertensives.
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Cost-effectiveness of the polypillThe main effect of choosing a different cut-point is that
the ICERs for the polypill scenarios decrease with lower
SCORE thresholds. Opportunistic screening combined
with the polypill without aspirin and doubling of the
statin doses (scenario 2C) had the most favourable ICER
with a SCORE threshold of 5%. For the other thresholds,
separate medication has the lowest ICER. It must be
noted, though, that the total health gain in the separate
medication scenario is only about 1/3 to 1/2 of the total
health gain of scenario 2C. We also performed separate
analyses by gender and age (table 6). For all scenarios,
the costs per QALY were higher for women than for men
in all age categories but remained far below the
threshold of V20000.
Figure 2 displays the range of values for costs and
effects (QALYs) in the cost-effectiveness plane for 7.5%
risk. It shows that most values cluster narrowly along
what can be imagined as a line, which has a slope in the
average cost-effectiveness ratio.
Figure 3 shows acceptability curves for the choice of
treatment strategy for 7.5% risk. For each cost-effective-
ness threshold (the maximum value below which
a treatment is accepted as being cost-effective or the
‘willingness to pay’), it gives the probability that the
treatment will be cost-effective. Thus, up to a level of
about V9000/QALY, separate medication is most likely
to be cost-effective but beyond that scenario 2C is most
likely the best alternative.
Variation of the costs of the most cost-effective polypill
(scenario 2C) showed that when the price of the pill
would be under V50 per year (excluding drug delivery
costs and including VAT), scenario 2C would become the
most favourable scenario when using a SCORE threshold
of 7.5%. In the present calculations, we estimated the
price of the polypill in scenario 2C to be V65.76 per year.
Probabilistic sensitivity analysis
Results of the sensitivity analysis are displayed in table 7
as 95% CIs for the outcomes measures, meaning that
95% of the simulations fell within the indicated ranges.
It can be observed that the ICERs are within a rather
small range. In that respect, results can be judged to be
robust. Nonetheless, there is some overlap between
intervals, meaning that the relative order of the different
medication compositions could be different. Table 8
shows the results of the analyses of the base case scenario
with different discount rates.
DISCUSSION
The results of this study suggest that opportunistic
screening and offering a polypill to people with
a minimum 10-year risk of cardiovascular mortality of
Table 4 Number of cases prevented over time by the polypill intervention at a 10-year risk of 7.5%
Scenario (PP intervention) AMI Stroke
Expected* 807 k 1374 k
Cases prevented Cases prevented
Number Percentage NNT Number Percentage NNT
Polypill scenario 2A 23.8 (8.3e41.6) k 2.89 (1.02e5.06) 31 36.1 (12.3e72.9) k 2.57 (0.86e5.12) 20
Polypill scenario 2B 22.5 (8.3e38.8) k 2.73 (1.00e4.70) 33 36.2 (12.3e72.9) k 2.57 (0.86e5.14) 20
Polypill scenario 2C 29.7 (10.5e52.4) k 3.60 (1.30e6.34) 25 47.4 (16.4e95.0) k 3.37 (1.17e6.78) 15
Separate medication
(scenario 3)
12.8 (4.9e21.0) k 1.55 (0.60e2.56) 46 19.9 (7.5e37.5) k 1.41 (0.53e2.61) 30
*According to reference scenario.
NNT, number needed to treat.
Table 5 Outcomes and ICERs (total costs per LY and QALY gained) compared with current practice
Outcomes Polypill scenario 2A Polypill scenario 2B Polypill scenario 2C
Separate medication
scenario 3
Risk threshold 5% 7.5% 10% 5% 7.5% 10% 5% 7.5% 10% 5% 7.5% 10%
Cost of intervention
(310
6 V)
954 907 870 921 876 840 967 914 872 331 319 309
Incremental healthcare
costs (310
6 V)
2210 1710 1320 1940 1500 1160 2240 1730 1330 750 720 690
Total incremental
costs (310
6 V)
3390 2830 2400 2860 2370 2000 3210 2640 2200 1080 1040 999
LYs gained (310
3) 425 314 236 395 291 218 474 349 261 154 147 141
QALYs gained (310
3) 360 266 195 335 244 182 408 296 221 132 126 122
ICER (310
3 V/LY) 8.0 9.0 10.2 7.2 8.2 9.1 6.8 7.6 8.5 7.0 7.0 7.1
ICER (310
3 V/QALY) 9.4 10.8 12.3 8.5 9.7 10.9 7.9 8.9 10.0 8.2 8.2 8.2
In the current practice scenario, the total costs of healthcare were 675310
9, total life years 165310
6 and total QALYs 128310
6.
ICERs, incremental cost-effectiveness ratios; LY, life years; QALY, quality-adjusted life years.
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Cost-effectiveness of the polypillbetween 5% and 10% is a cost-effective strategy in the
primary prevention of CVDs. This is the case, whether
the threshold chosen is 5%, 7.5% or 10%, but the lower
the threshold, the lower the incremental cost-effective-
ness ratio. All three differently composed polypills were
cost-effective compared with usual care, as was the single
drug option. The polypill without aspirin but with
a double dose of simvastatin leads to most health gains
with all risk thresholds. At a 10-year risk of cardiovascular
death of $7.5%, such a strategy would lead to an esti-
mated decrease in the incidence of myocardial infarc-
tion and stroke of about 3.5%, at a cost of V8900 per
QALY. This is well below the consensual threshold of
V20000 per QALY.
40 Separate medication, targeted at
hypertension and/or hypercholesterolaemia, is the most
cost-effective strategy compared with usual care in the
risk classes of 7.5%, respectively 10%, or above. However,
total health gains are substantially lower.
Both the strengths and weaknesses of our study revolve
around the weak basis of clinical evidence and the use of
mathematical modelling. The latter allowed an explor-
atory investigation based on preliminary results of
a phase II clinical trial, thus providing insights into the
range of health beneﬁts that can be expected. But with
the lack of evidence of efﬁcacy with regard to established
clinical endpoints, the results should certainly not be
taken as a precise estimate of the cost-effectiveness. We
took into account what seemed to be the most important
factors determining cost-effectiveness.
Since Wald and Law’s 2003 article, the appealing idea
of a highly effective and safe polypill taken once daily to
prevent CVD has gained widespread attention. Soon, the
question of cost-effectiveness was raised. Thus, Franco
and colleagues developed a model to estimate the
maximum price of the polypill for it still to be cost-
effective in the primary prevention of CVD.
41 As input,
they used the hypothetical effectiveness estimates from
Wald and Law’s article and applied them to a population
with the characteristics of the Framingham and
Framingham offspring study cohort. This population was
classiﬁed into three classes according to 10-year coronary
heart disease risk using a risk score (the Anderson
equation). Costs were calculated on the basis of unit
costs valid for the healthcare system in the Netherlands.
The calculations showed that the pill would be cost-
effective (<V20000 per year of life saved) as long as the
yearly costs of the pill would be below approximately
V270 in high-risk groups and V160 in intermediate-risk
groups (10%e20% risk). Indeed, with the yearly costs of
the polypill we assumed in our study, which were far
below this threshold, we found all scenarios to be cost-
effective. This was despite the fact that the effectiveness
estimates we used were much lower than those of Wald
and Law’s.
These lower estimates are due to insights gained since
then, as steps towards realisation of the polypill concept
have been taken. Several prototypes have been devel-
oped and large-scale clinical trials are currently under
way. Yet, the only clinical evidence so far concerns a brief
randomised trial of 12 weeks of treatment, the Polycap
Study. On the basis of this limited evidence, it was
concluded that the pill seems safe and that the effects on
Table 6 Outcomes and ICERs compared with current practice
Outcomes Polypill scenario 2A Polypill scenario 2B Polypill scenario 2C
Separate medication
scenario 3
Sex\age 40e
49
50e
59
60e
69
70e
75
40e
49
50e
59
60e
69
70e
75
40e
49
50e
59
60e
69
70e
75
40e
49
50e
59
60e
69
70e
75
ICER (310
3
V/QALY)
Men 6.9 7.8 8.3 11.4 6.0 6.8 7.4 10.3 5.3 5.9 6.7 9.6 4.2 4.4 6.0 9.6
Women NA 8.9 13.9 17.2 NA 8.7 13.7 16.7 NA 8.4 12.6 15.8 NA 8.7 11.0 14.8
Age- and sex-speciﬁc data for the 7.5% risk numbers in table 5.
ICERs, incremental cost-effectiveness ratios; QALY, quality-adjusted life years.
Figure 3 Acceptability curves for the choice of treatment
strategy.
Figure 2 Cost-effectiveness plane: scatter plot of costs and
quality adjusted life years (QALYs).
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Cost-effectiveness of the polypillblood pressure and cholesterol are not inferior to the
individual substances given separately. However, it must
be said that the effects on these intermediate endpoints
fall well below the rough estimates made by Law and
Wald, who calculated that up to 80% of all cardiovascular
events in the population at large could be prevented.
There are two main sources for the discrepancy between
their estimates and our calculations. First, both the
estimated effects on intermediate endpoints and the RR
reductions (per unit of risk factor level reduction) Law
and Wald used seem to have been too optimistic.
Second, we did not consider the introduction of the
polypill in the ‘universal’ manner envisioned in their
original article. It seems very unlikely that medicalisation
of a whole population will ever ﬁnd wide support.
Instead, we imagined a situation in which the polypill
would be introduced within the current context of
cardiovascular risk management and primary preven-
tion. This approach is in line with current views on
focusing on those at increased risk and ﬁnding ways of
identifying them.
42 Only limited experience exists with
this type of primary prevention, which might be best
described as opportunistic screening.
43 Hence, we had
to make several assumptions to estimate the number of
individuals who would ultimately take the polypill. These
include the preparedness of GPs to engage in opportu-
nistic screening, the proportion of eligible individuals
who are willing to choose lifelong medication and their
compliance with treatment. Many will probably prefer
changing their lifestyles or will start but not continue. A
lack of compliance obviously reduces cost-effectiveness,
as investments are made that do not pay out in terms of
health gains. On the other hand, the combination of
drugs in one pill takes away an obstacle to compliance in
patients requiring more than one drug.
44e46 47 Litera-
ture shows that adherence to medication declines with
the number of drugs prescribed.
44 48 49
Especially in primary prevention, the safety and side
effects of a drug are of crucial concern. As far as statins
are concerned, the most serious complication is rhab-
domyolysis, which is very rare, but can be fatal. More
frequent are complaints of muscle pain.
50 However,
a review and meta-analysis of Weng et al
34 of 75 trials
showed that the incidence of muscle toxicity was low in
all trials. The most recent Cochrane meta-analysis did
not ﬁnd signiﬁcant differences between placebo and
treatment groups. The most important consequence
would be that the relatively minor side effects would
reduce adherence or lead to discontinuation, an effect
that is indirectly included in our model (via reduced
compliance). The same applies to the side effects of the
blood pressure-lowering components. In particular,
cough caused by an ACE inhibitor, which is independent
of the dose, could lead to discontinuation of the pill.
28
Aspirin can cause gastrointestinal bleedings and
hemorrhagic stroke.
38 51 52 The latter more or less annul
the protective effect on ischaemic stroke, such that the
net effect is neutral. The increased risk of gastrointes-
tinal bleeding, which we took into account, further
contributed to the relatively unfavourable proﬁle of
a polypill containing aspirin, which turned out to be the
least cost-effective option.
To gain more deﬁnite insights into the cost-effective-
ness of the polypill in the opportunistic screening
setting, two major ‘unknowns’ need to be clariﬁed. First,
the results of large-scale phase III clinical trials will have
to show how the effects on intermediate endpoints
translate into clinical beneﬁt. In particular, they will
need to answer the question whether the ‘sum is greater
than the parts’, both with regard to beneﬁts as to safety.
Second, more needs to be known about the willingness
to participate in opportunistic screening initiatives. This
applies to eligible persons and to GPs. Also the practical
Table 8 Sensitivity analyses with different discount rates
(7.5% risk)
Discount
rates:
costs,
effects
Polypill
scenario
2A
Polypill
scenario
2B
Polypill
scenario
2C
Separate
medication
scenario 3
4%, 1.5% 10800 9700 8900 8200
0%, 0% 17300 16200 15100 14200
3%, 3% 16400 14900 13700 12600
5%, 5% 16200 14200 12900 11800
Table 7 Results of the probabilistic sensitivity analysis
Outcomes Polypill scenario 2A Polypill scenario 2B Polypill scenario 2C Separate medication
Cost of intervention (310
6 V) 380 to 1510 370 to 1460 380 to 1540 290 to 360
Incremental healthcare costs
(310
6 V)
580 to 2630 560 to 2570 640 to 2980 290 to 1140
Total incremental costs
(310
6 V)
1070 to 4450 940 to 4000 1040 to 4490 610 to 1460
LYs gained (310
3) 113 to 517 110 to 507 130 to 613 59 to 241
QALYs gained (310
3) 92 to 424 92 to 427 109 to 519 50 to 206
ICER (310
3 V/LY) 8.2 to 10.7 7.4 to 9.8 6.9 to 9.0 5.9 to 10.8
ICER (310
3 V/QALY) 9.9 to 13.0 8.8 to 11.7 8.1 to 10.7 6.9 to 12.6
Displayed are 95% CIs of the model outcomes for a 10-year risk threshold of 7.5%.
ICERs, incremental cost-effectiveness ratios; LY, life years; QALY, quality-adjusted life years.
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Cost-effectiveness of the polypillconsequences and logistic difﬁculties in implementing
opportunistic screening will need to be addressed.
Implications
Primary prevention is increasingly seen as a crucial tool
in further reducing the burden of CVD. In a healthcare
system such as that of the Netherlands, in which the GP
occupies a central role, opportunistic screening is
a feasible strategy of which the beneﬁts are currently
being actively explored. Thus, in the Netherlands
opportunistic screening for cardiovascular disease by the
GPs has recently been introduced and reimbursement
has been recommended. Obviously, in order to make
most out of this opportunity, insights into the relative
cost-effectiveness of alternative preventive measures for
those at increased risk is essential, as are the implications
on effects and costs over a long time. Low doses of
aspirin are not recommended in the Dutch guideline in
the primary prevention of CVDs.
18 This is based on the
adverse effects like gastrointestinal bleedings and
hemorrhagic stroke caused by aspirin.
51 52 The advan-
tage of using a polypill without aspirin is that these
adverse effects due to aspirin could be avoided.
Since the introduction of the concept of a polypill by
Wald and Law, there were different changes in the
composition and dosage of the medication put into this
pill. One can expect that in the future further changes in
the composition and dosage will lead to a better-
balanced pill. For example, ACE antihypertensive drugs
often cause an unpleasant tickling cough. Replacement
with a selective type 1 angiotensin II-receptor (AT1)
antagonist could solve this problem.
Guidelines on primary prevention cardiovascular
suggest ﬁrst to start with lifestyle changes such as
increasing physical activity and diet advices. In our
calculations, we did not include the costs and the effects
of a lifestyle advisor.
Conclusions
The polypill or variants thereof seem to offer an efﬁcient
way to reduce the CVD burden. Opportunistic screening
of the population of $40 years to select individuals with
a mild to moderately increased risk for CVDs, followed
by polypill prescription, would prevent approximately
3.5% of all cardiovascular events. The cost-effectiveness
of all variants is within the same order of magnitude.
Therefore, other aspects will determine which composi-
tion of pill is to be preferred, such as side effect proﬁle
and total health gains. Based on these criteria, our study
suggests that the polypill without aspirin and a double
statin dose is the most favourable option.
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